Ignite Creation Date:
2024-05-06 @ 8:27 PM
Last Modification Date:
2024-10-26 @ 3:27 PM
Study NCT ID:
NCT06381830
Status:
RECRUITING
Last Update Posted:
2024-04-24
First Post:
2024-04-19
Brief Title:
Clinical Study of CAR-T Cell Therapy Following ASCT for RR B-cell Non-Hodgkins Lymphoma
Sponsor:
The First Affiliated Hospital of Soochow University
Organization:
The First Affiliated Hospital of Soochow University
Study Overview
Official Title:
Clinical Study of the Efficacy and Safety of Chimeric Antigen Receptor T-cell Therapy Following Autologous Stem Cell Transplantation for RelapsedRefractory B-cell Non-Hodgkins Lymphoma
Status:
RECRUITING
Status Verified Date:
2024-03
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
The study is designed to evaluate the efficacy and safety of chimeric antigen receptor T-cell therapy following autologous stem cell transplantation for relapsedrefractory B-cell Non-Hodgkins lymphoma
Detailed Description:
Chimeric antigen receptor T CAR-T cell therapy has emerged as a promising approach for relapsed or refractory B-cell Non-Hodgkins lymphoma RR B-NHL with a complete response CR rate of about 50 It is also considered to be a reasonable consolidation option in low or unmeasurable disease states recently Unfortunately 40-70 of patients experienced relapse after CAR-T cell therapy in the long-term follow up Autologous stem cell transplantation ASCT with myeloablative chemotherapy can enhance the efficiency of CAR-T cells and alleviate tumor load leading to a lower relapse rate As a result CAR-T cell therapy following ASCT may be a promising method for RR LBCL patients
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
False
Is a FDA Regulated Device?:
False
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None